With a high consumption of GBCAs worldwide and recommendations to reduce the dose of gadolinium, Elucirem™ uses 50% less gadolinium with benefits that go beyond image quality1-9
MRI use has increased dramatically in recent years with a high consumption of GBCAs worldwide2-4
* Scans included may or may not have used a contrast agent. † Exams outside hospital not included.
Each year 30 million doses of GBCA are consumed worldwide as of 20144Major health authorities and medical associations recommend reducing the dose of gadolinium whilst maintaining image quality5,6
Following reports of NSF and gadolinium deposition, the European Medicines Agency (EMA) and European Society of Urogenital Radiology (ESUR) recommend:
Macrocyclic GBCAs can continue to be used in their current indications but at the lowest doses for sufficient image enhancement and only when unenhanced scans are not appropriate.5
Emergency examination: For all patients, use the lowest dose of contrast medium consistent with a diagnostic result.6
Pregnancy and lactation: When there is a very strong indication for enhanced MRI, the smallest possible dose of a macrocyclic gadolinium contrast agent may be given to the pregnant female.6
No dose adjustment needed in your renally impaired or pediatric patients (>2 years of age)1
Simulation for educational purposes only, the data shown does not reflect a real patient case. The sensitivity and specificity of Elucirem™ for detection of specific pathology are not known.
• Conventional GBCAs: 943.5 mg Gd /year x 45 years = 42.5g of Gd.
• Elucirem™: 471.6 mg Gd /year x 45 years = 21.2g of Gd.
Want to know more about Elucirem™’s (gadopiclenol) innovative mechanism of action?
GBCA: Gadolinium-Based Contrast Agent
MRI: Magnetic Resonance Imaging
NSF: Nephrogenic Systemic Fibrosis
References
1. Elucirem Summary of Product Characteristics. 2023.
2. Health at a Glance 2019: OECD Indicators. https://www.oecd-ilibrary.org/sites/eadc0d9d-en/index.html?itemId=/content/component/eadc0d9d-en. Accessed November 2023.
3. Health at a Glance 2021: OECD Indicators. https://www.oecd-ilibrary.org/sites/ed023875-en/index.html?itemId=/content/component/ed023875-en. Accessed November 2023.
4. Runge VM. Safety of the gadolinium-based contrast agents for magnetic resonance imaging, focusing in part on their accumulation in the brain and especially the dentate nucleus. Invest Radiol. 2016;51(5):273-279
5. PRAC confirms restrictions on the use of linear gadolinium agents. Benefit-risk balance of certain linear gadolinium agents no longer favourable. European Medicines Agency, 2017.
6. European Society of Urogenital Radiology. ESUR Guidelines on Contrast Agents. https://www.esur.org/wp-content/uploads/ 2022/03/ESUR-Guidelines-10_0-Final-Version.pdf. Accessed November 2023.
7. Loevner LA, Kolumban B, Hutóczki G, et al. Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial. Invest Radiol. 2023 May 1;58(5):307-313.
8. Kuhl C, Csőszi T, Piskorski W, et al. Efficacy and safety of half-dose gadopiclenol versus full-dose gadobutrol for contrast-enhanced body MRI. Radiology. 2023 Jul;308(1):e222612.
9. Brünjes R, Hofmann T. Anthropogenic gadolinium in freshwater and drinking water systems. Water Res. 2020;182:115966.
10. Prohance Summary of Product Characteristics. 2021.
11. MultiHance Summary of Product Characteristics. 2021.
12. Gadovist Summary of Product Characteristics. 2022.
13. Saslow D, Boetes C, Burke W, et al. American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89.
14. Lee CS, Monticciolo DL, Moy L. Screening Guidelines Update for Average-Risk and High-Risk Women. AJR Am J Roentgenol. 2020 Feb;214(2):316-323.
Trademarks are the property of their respective owners.
Click here for the SmPC. For more information, please refer to your local product information